Associate Director, Investor Relations

The Company

It’s not often you get the chance to make a real impact on the lives of others, while expanding your own possibilities. You’ll find that rare opportunity at Pharma Essentia USA Corporation (PEC). Join us, and let’s transform lives, together.

It’s not often you get the chance to make a real impact on the lives of others, while expanding your own possibilities. You’ll find that rare opportunity at Pharma Essentia USA Corporation (PEC). Join us, and let’s transform lives, together.

Pharma Essentia USAis a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in the United Statesand a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking.

Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today we are listed on the Taipei Exchange (6446) and are expanding our global presence with operations in the U.S., Japan, South Korea and China, along with a world-class biologics production facility in Taichung.

We are seeking an experienced Associate Director, Investor Relations to help build and execute Pharma Essentia’s U.S. investor relations capability. This role will strengthen engagement with the global investment community, expand awareness among U.S. healthcare investors, and translate the company’s scientific, clinical, commercial, and strategic priorities into a clear investment narrative.

The Associate Director will serve as a key liaison with current and prospective institutional investors, sell-side analysts, investment banks, and other capital markets stakeholders. The role requires close partnership with senior leadership and teams across Corporate Strategy, Corporate Communications, Finance, Commercial, Medical Affairs, R&D, Legal, and other functions.

• Develop and execute a U.S. institutional investor engagement strategy aligned with corporate objectives, key milestones, and growth priorities.
• Build and maintain relationships with current and prospective institutional investors, including U.S. healthcare-focused funds and specialist biotechnology investors.
• Develop and maintain relationships with sell-side analysts, investment banks, and capital markets advisors.
• Develop and manage the investor engagement calendar, including healthcare conferences, scientific congresses, non-deal roadshows, investor days, and targeted management meetings.
• Prepare senior executives for investor meetings with briefing materials, investor profiles, anticipated questions, talking points, and Q&A support.
• Lead development of the investment narrative and prepare investor-facing materials, including corporate decks, earnings materials, R&D Day presentations, public presentations, executive briefings, investor FAQs, and the quarterly Q&A book.
• Partner with Corporate Communications on press releases and other public disclosures relevant to investors, ensuring messaging is consistent, accurate, and appropriate for investors and capital markets stakeholders.
• Maintain data and provide management insights on shareholder composition, ownership changes, investor targeting activity, investor sentiment, analyst commentary, peer-company valuation, and broader market trends.

• 7+ years of relevant experience in investor relations, biotechnology equity research, healthcare investment banking, healthcare investing, corporate strategy, corporate development, or a related capital markets role.
• Significant experience in biotechnology, pharmaceuticals, or broader life sciences. Experience in hematology, oncology, immunology, rare disease, or specialty pharmaceuticals strongly preferred.
• Existing relationships with, or substantial experience interacting with, healthcare-focused institutional investors, sell-side analysts,…